Extending the specificity of the DAT reagents in specific clinical situations

  • For the investigation of those clinical situations where the presence of hemolysis has been established or is suspected, to distinguish immune from nonimmune hemolytic anemia
  • For the investigation of :

Ø  Autoimmune hemolytic anemia (AIHA)

Ø  Hemolytic disease of the fetus and neonate (HDFN)

Ø  Hemolytic transfusion reactions (HTR)

Ø  Hemolytic reactions related to allogeneic stem cell transplant or solid organ transplant

Ø  Drug-induced immune hemolytic anemia (DIHA)

We are excited to announce our new immunohematology tool that evaluates positive direct antiglobulin test (DAT) samples in gel technology. DG Gel DC Scan Plus investigates those clinical situations where the presence of hemolysis has been established, or is suspected, to distinguish immune from nonimmune hemolytic anemia, to help determine the best treatment in each case.

DG Gel DC Scan Plus improves patient care by extending the specificity of the DAT reagents beyond routine anti-IgG and anti-C3d, increasing sensitivity and specificity, and improving clinical patient management and outcomes in AIHA. Furthermore, it unifies and simplifies testing protocols to help you make the right decision based on diagnostic evidence. Timely results increase your efficiency and let you start the appropriate treatment and avoid undesired situations.